Lv21
110 积分 2023-02-07 加入
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial
13小时前
求助中
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial
13小时前
已完结
Dilation after small biliary sphincterotomy
1个月前
已完结
Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients
2个月前
已完结
Association Between Vonoprazan and the Risk of Gastric Cancer After Helicobacter pylori Eradication
2个月前
已完结
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)
2个月前
已完结
伏诺拉生联合铋剂等四联疗法治疗幽门螺杆菌感染的效果探讨
2个月前
已完结
Sa1365 A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VONOPRAZAN-BASED VERSUS ESOMEPRAZOLE-BASED BISMUTH-CONTAINING QUADRUPLE THERAPY FOR THE ERADICATION OF HELICOBACTER PYLORI INFECTION IN CHINA
2个月前
已完结
437 – An Open-Label, Multi-Center, Randomized, Superiority Trial of Vonoprazan Versus Esomeprazole As Part of First-Line Triple Therapy for Helicobacter Pylori Infection
2个月前
已关闭
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial
2个月前
已完结
皖公网安备34019202002308
